Antiinflammatory Therapy and Cardiovascular Events

Canakinumab targets a proinflammatory cytokine implicated in the development of atherothrombotic plaques. Whether reducing inflammation without lowering cholesterol would prevent cardiovascular events is unclear. New research findings are summarized in this short video. Full study: http://nej.md/2wrjwxP

Watch more Quick Take videos: http://nej.md/quick-take
+